Table 1. Oligonucleotide and primer sequences used in this study.
| Name | Sequence1 | Length (nt) |
|---|---|---|
| Synthesis of spaED sequence | ||
| spaED 1 | 5’-taccatggcgcaacacgatgaagctcaacaaaatgctttttatcaagtgt-3’ | 50 |
| spaED 2 | 5’-ctttttatcaagtgttaaatatgcctaacttaaacgctgatcaacgtaat-3’ | 50 |
| spaED 3 | 5’-gctgatcaacgtaatggttttatccaaagccttaaagatgatccaagcca-3’ | 50 |
| spaED 4 | 5’-agatgatccaagccaaagtgctaacgttttaggtgaagctcaaaaactta-3’ | 50 |
| spaED 5 | 5’-aagctcaaaaacttaatgactctcaagctccaaaagctgatgcgcaacaa-3’ | 50 |
| spaED 6 | 5’-gctgatgcgcaacaaaataacttcaacaaagatcaacaaagcgccttcta-3’ | 50 |
| spaED 7 | 5’-acaaagcgccttctatgaaatcttgaacatgcctaacttaaacgaagcgc-3’ | 50 |
| spaED 8 | 5’-acttaaacgaagcgcaacgtaacggcttcattcaaagtcttaaagacgac-3’ | 50 |
| spaED 9 | 5’-agtcttaaagacgacccaagccaaagcactaatgttttaggtgaagctaa-3’ | 50 |
| spaED 10 | 5’-tttaggtgaagctaaaaaattaaacgaatctcaagcaccgaaa-3’ | 43 |
| spaED comp 2 | 5’-attacgttgatcagcgt-3’ | 17 |
| spaED comp 4 | 5’-taagtttttgagcttcac-3’ | 18 |
| spaED comp 5 | 5’-ttgttgcgcatcagcttttg-3’ | 20 |
| spaED comp 6 | 5’-tagaaggcgctttgttg-3’ | 17 |
| spaED comp 8 | 5’-gtcgtctttaagactttg-3’ | 18 |
| spaED comp 10 | 5’-tttcggtgcttgagattc-3’ | 18 |
| pCB-spaED-GFP2a-CP BaMV viral vector construction | ||
| N-fus F | 5’-taaccggtccatggcgcaacac-3’ (AgeI) | 22 |
| N-fus R | 5’-taaccggttttcggtgcttgag-3’ (AgeI) | 22 |
| pCB-GFP-spaED2a-CP BaMV viral vector construction | ||
| C-fus F | 5’-tagcggccgctaccatggcgcaacac-3’ (NotI) | 26 |
| C-fus R | 5’-tagcggccgctttcggtgcttgag-3’ (NotI) | 24 |
| Amplification of inserts within BaMV viral vector | ||
| 5703 | 5’-aggcatcctatataatatac-3’ | 20 |
| BCP-N’ | 5’-ccaaacactaagcagtggat-3’ | 20 |
1 The restriction enzyme recognition sequences were underlined.